LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
暂无分享,去创建一个
C. Croce | P. Gasparini | F. Lovat | M. Fassan | H. Ishii | A. Vecchione | M. Barbareschi | G. Baldassarre | E. Galligioni | M. Schiappacassi
[1] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[2] J. Goodwin,et al. Decline in the use of anthracyclines for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Marc E. Lenburg,et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.
[4] J. Zhao,et al. Down-regulation of leucine zipper putative tumor suppressor 1 is associated with poor prognosis, increased cell motility and invasion, and epithelial-to-mesenchymal transition characteristics in human breast carcinoma. , 2011, Human pathology.
[5] L. Esserman,et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.
[6] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[7] Xiaodong Sun,et al. Down-regulation of tumor suppressor gene FEZ1/LZTS1 in breast carcinoma involves promoter methylation and associates with metastasis , 2009, Breast Cancer Research and Treatment.
[8] N. Samadi,et al. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis , 2009, Oncogene.
[9] C. Hansch,et al. Taxane Analogues against Breast Cancer: A Quantitative Structure–Activity Relationship Study , 2008, ChemMedChem.
[10] C. Croce,et al. Fez1/Lzts1-deficient mice are more susceptible to N-butyl-N-(4-hydroxybutil) nitrosamine (BBN) carcinogenesis. , 2008, Carcinogenesis.
[11] F. Cognetti,et al. HER2 and response to paclitaxel in node-positive breast cancer. , 2008, The New England journal of medicine.
[12] C. Rudin,et al. Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[13] W. Robinson,et al. Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer , 2007, International Journal of Gynecologic Cancer.
[14] D. Heron,et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] C. Croce,et al. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. , 2007, Cancer cell.
[16] L. Mariani,et al. Reduced FEZ1/LZTS1 expression and outcome prediction in lung cancer. , 2005, Cancer research.
[17] P. Johnston,et al. Molecular mechanisms of drug resistance , 2005, The Journal of pathology.
[18] C. Croce,et al. Collecting duct carcinoma of the kidney: an immunohistochemical study of 11 cases , 2004, BMC urology.
[19] William J. Gradishar,et al. Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer , 2004, Clinical Cancer Research.
[20] M. Jordan,et al. Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.
[21] K. Uzawa,et al. Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas. , 2003, International journal of oncology.
[22] J. Minna,et al. Differential expression of FEZ1/LZTS1 gene in lung cancers and their cell cultures. , 2002, Clinical Cancer Research.
[23] C. Croce,et al. FEZ1/LZTS1 is down-regulated in high-grade bladder cancer, and its restoration suppresses tumorigenicity in transitional cell carcinoma cells. , 2002, The American journal of pathology.
[24] Hansjuerg Alder,et al. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] A. C. Chinault,et al. Functional identification of LZTS1 as a candidate prostate tumor suppressor gene on human chromosome 8p22 , 2001, Oncogene.
[26] M. Rugge,et al. Fez1/lzts1 alterations in gastric carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] C. Croce,et al. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] N Kumar,et al. Taxol-induced polymerization of purified tubulin. Mechanism of action. , 1981, The Journal of biological chemistry.
[29] P. Schiff,et al. Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins. , 1981, Biochemistry.
[30] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[31] L. Fallowfield,et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] C. Criscitiello,et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[34] R. Donehower,et al. Drug therapy : paclitaxel (Taxol) , 1995 .
[35] B R Goldspiel,et al. Paclitaxel (Taxol) , 1994, Pharmacotherapy.